American Association for Cancer Research
00085472can152116-sup-153614_2_supp_0_k3hdvs.pdf (13.87 kB)

Supplementary Table S5 from An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells

Download (13.87 kB)
journal contribution
posted on 2023-03-31, 00:07 authored by Claudia Peitzsch, Monica Cojoc, Linda Hein, Ina Kurth, Katrin Mäbert, Franziska Trautmann, Barbara Klink, Evelin Schröck, Manfred P. Wirth, Mechthild Krause, Eduard A. Stakhovsky, Gennady D. Telegeev, Vladimir Novotny, Marieta Toma, Michael Muders, Gustavo B. Baretton, Fiona M. Frame, Norman J. Maitland, Michael Baumann, Anna Dubrovska

Regulation of the genes involved in WNT signaling pathway in the ALDH+ population of DU145 radioresistant (RR) cells versus ALDH- population of DU145 RR cells.





Radiotherapy is a mainstay of curative prostate cancer treatment, but risks of recurrence after treatment remain significant in locally advanced disease. Given that tumor relapse can be attributed to a population of cancer stem cells (CSC) that survives radiotherapy, analysis of this cell population might illuminate tactics to personalize treatment. However, this direction remains challenging given the plastic nature of prostate cancers following treatment. We show here that irradiating prostate cancer cells stimulates a durable upregulation of stem cell markers that epigenetically reprogram these cells. In both tumorigenic and radioresistant cell populations, a phenotypic switch occurred during a course of radiotherapy that was associated with stable genetic and epigenetic changes. Specifically, we found that irradiation triggered histone H3 methylation at the promoter of the CSC marker aldehyde dehydrogenase 1A1 (ALDH1A1), stimulating its gene transcription. Inhibiting this methylation event triggered apoptosis, promoted radiosensitization, and hindered tumorigenicity of radioresistant prostate cancer cells. Overall, our results suggest that epigenetic therapies may restore the cytotoxic effects of irradiation in radioresistant CSC populations. Cancer Res; 76(9); 2637–51. ©2016 AACR.